Welcome to our dedicated page for AI / ML INNOVATIONS news (Ticker: AIMLF), a resource for investors and traders seeking the latest updates and insights on AI / ML INNOVATIONS stock.
AI/ML Innovations Inc. (AIMLF) is a pioneering company in the artificial intelligence (AI) and machine learning (ML) sectors, dedicated to acquiring and advancing technologies that address critical societal needs. Established to capitalize on the burgeoning fields of AI and ML, the company focuses on emerging digital health and wellbeing solutions that leverage AI, cloud computing, and digital platforms to revolutionize healthcare management.
AI/ML Innovations Inc. is committed to transforming healthcare through strategic partnerships and innovative initiatives. Its majority-owned subsidiary, Health Gauge Inc., is at the forefront of health tech innovation. Health Gauge has developed the ‘Follow Your Heart’ smartwatch, a wellness tool that uses proprietary AI PrecisionPulse Neural Network measurement technology to provide non-invasive, medical-grade accurate blood pressure readings. This product is a significant step forward in addressing the hypertension epidemic, offering users convenient and precise health monitoring.
In addition to consumer products, AI/ML Innovations Inc. supports healthcare innovators and researchers with advanced tools like The Pulse Guru, a smart sensor wearable that offers unparalleled access to raw ECG and PPG signal data. This device is instrumental for professionals needing detailed cardiovascular insights.
The company’s strategic growth also includes a recent acquisition of Naiad Labs Inc.’s product division, integrating the Long ECG Neural Net, which drastically reduces the time needed to label long ECGs, enhancing accuracy and efficiency in cardiovascular diagnostics.
AI/ML Innovations Inc. continues to expand its technological footprint with the launch of NeuralCloud Solutions Incorporated, a subsidiary focused on merging smart sensor technology with digital health. The company aims to make high-quality personal biometric data accessible to individuals globally, supported by robust AI and neural network technologies.
AI/ML Innovations Inc. trades on the Canadian Securities Exchange under the symbol AIML, the OTCQB Venture Market under AIMLF, and the Frankfurt Stock Exchange under 42FB. For more information, visit the company's website.
AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) announced a marketing services agreement with Octagon Media Corp to enhance its digital media presence. The contract, lasting three months, involves monthly payments of US$25,000 and the issuance of 500,000 stock options at CAD$0.20. Additionally, the company granted 800,000 options to management at the same exercise price. Through strategic partnerships and a focus on AI and ML technologies, AI/ML aims to drive growth in the healthcare sector.
AI/ML Innovations Inc. announced a License Agreement with MedWatch Technologies, Inc. to utilize patented health management technology and AI software for diabetes monitoring solutions. MedWatch will pay Health Gauge an annual fee of US$120,000 plus a 2% royalty on gross sales. With diabetes-related medical costs in the US at $327 billion annually, the partnership aims to improve patient outcomes through non-invasive monitoring tools. The agreement spans an initial term of 7 years, with a US$2 million termination fee.
AI/ML Innovations Inc. announced a license agreement with MedWatch Technologies for its patented health management technology, targeting the $327 billion US diabetes market. MedWatch will pay an annual fee of US$120,000 plus a 2% royalty on gross sales, projected to be US$5.00 to US$8.00 per device. The agreement has an initial term of 7 years with automatic renewals and includes a US$2 million early termination fee. This strategic partnership aims to enhance diabetes management through innovative blood glucose monitoring solutions.
AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) has completed a non-brokered private placement, issuing 4 million units at $0.15 per unit, resulting in $600,000 in gross proceeds. Each unit consists of one common share and one share purchase warrant, exercisable at $0.20 for 12 months. The funds will support platform deployment with healthcare clients and general operating expenses. The company incurred $25,337.81 in finder's fees for this offering.
AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) announced that its subsidiary, Tech2Heal SAS, has been selected as a founding participant in the PariSanté Health Tech Campus in Paris, France. This initiative aims to foster collaboration among leading health-tech entities to enhance research and innovation in e-health. Tech2Heal's recognition reflects its leadership in digital mental healthcare. The campus includes prominent players like Inserm and Health Data Hub, providing Tech2Heal access to a rich ecosystem of expertise to strengthen its healthcare solutions.
AI/ML Innovations Inc. announces that its subsidiary, Health Gauge, has received a patent (US Patent No. 11183303) for its wearable health monitoring technology. This technology utilizes machine learning to enhance the accuracy of health metrics such as blood pressure, enabling users to achieve personal health goals. Key features include predictive health analysis and behavioral insights based on data from various bio-signals. The patent solidifies Health Gauge's position in the AI-supported telemedicine field, aimed at improving health monitoring during and beyond the pandemic.
AI/ML Innovations (CSE:AIML)(OTCQB:AIMLF) announces a SaaS licensing agreement between its subsidiary Health Gauge and Rapid Test & Trace Canada (RTTC) for a COVID-19 testing solution. Health Gauge will earn up to $2.50 per test plus additional fees. The contract grants RTTC exclusive rights in Canada, the U.S., Mexico, Australia, and the U.K., contingent upon achieving a minimum of 50,000 tests monthly per country by March 1, 2022. Deployment is expected within 30 days. This agreement is projected to generate substantial recurring revenue for Health Gauge.
AI/ML Innovations Inc. has announced its first SaaS licensing contract through its subsidiary, Health Gauge, with Rapid Test & Trace Canada (RTTC) for a COVID testing solution. The agreement allows Health Gauge to receive up to $2.50 per test, with a minimum of 50,000 tests per month required across five countries by March 2022. Deployment of the solution is anticipated within 30 days. The partnership aims to enhance COVID testing verification for RTTC's large corporate clientele.
AI/ML Innovations Inc. (CSE:AIML; OTCQB:AIMLF) has successfully completed its Warrant Early Exercise Incentive Program, resulting in the exercise of 2,288,000 warrants. This has led to the issuance of 1,144,000 common shares and raised $572,000 in working capital. The company is focused on advancing Artificial Intelligence and Machine Learning technologies, particularly in digital health. Through strategic partnerships, it aims to enhance healthcare management solutions.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) announced its subsidiary AI Rx Inc. is ready to launch its Tech2Heal product portfolio in the US, focusing on digital behavioral health. To aid market entry, AIML retained Oxygen Enterprises Inc. to develop a market strategy and facilitate key partnerships. AIML will compensate Oxygen with CDN $80,000, 100,000 shares, and 100,000 stock options. The company's strategy leverages AI and machine learning technologies to advance healthcare solutions, aiming for significant growth in the digital health sector.
FAQ
What is the current stock price of AI / ML INNOVATIONS (AIMLF)?
What is the market cap of AI / ML INNOVATIONS (AIMLF)?
What does AI/ML Innovations Inc. do?
What is 'Follow Your Heart'?
What are the key features of The Pulse Guru?
What recent acquisitions has AI/ML Innovations Inc. made?
What is NeuralCloud Solutions Incorporated?
How does AI/ML Innovations Inc. plan to expand its market presence?
Where can I buy AI/ML Innovations Inc. products?
What is the Neural Net Store?
How does AI/ML Innovations Inc. support the healthcare industry?
What is the significance of the Long ECG Neural Net?
